![]() |
市場調查報告書
商品編碼
1439494
血栓管理設備 - 全球市場考量、競爭格局、市場預測 (2030)Clot Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
全球血栓管理設備市場規模到2023年將達到17.6億美元,2030年將達22.9億美元,預計2024-2030年期間複合年增長率為4.50%。 對血栓管理設備的需求主要是由於老年人口的增加(他們構成了血栓形成風險的大部分人口)以及與生活方式相關的疾病(例如高血壓和肥胖)的患病率不斷增加,從而顯著增加了血栓形成的可能性產品開發創新推動了第二代血栓清除設備的開發,最終推動了預測期內血栓管理設備市場的整體成長。
血栓管理設備的市場動態
在血栓管理設備市場,由於多種因素,產品需求不斷增加。 主要因素之一是人口老化的加劇。 世界衛生組織(WHO)在《健康老化十年(2020-2030)》報告中提供的數據證明了這一點,該報告顯示,60歲及以上的人口數量將增加34%,從2019年的10億增加到2019年的10億。2030 年。到 2020 年,這一數字將增至 14 億。 到 2050 年,世界老年人口將增加一倍以上,達到 21 億。 除上述統計數據外,世界衛生組織發布的一份關於心血管疾病的情況說明書指出,超過五分之四的心血管疾病死亡主要是由於中風和心臟病發作,其中三分之一的死亡人數為70歲以上的人受到影響。 年齡較大和年齡被認為是許多疾病的主要危險因素,並且增加了發生深部靜脈血栓(DVT)等血栓的可能性。 DVT 的主要併發症之一是肺栓塞,這對患者來說可能是致命的。 因此,為了避免此類血栓形成的嚴重後果,需要使用下腔靜脈過濾器等血栓管理裝置。 因此,老年人口的增加可能會導致 DVT 病例增加,並進一步推動對血栓管理設備的需求,從而促進預測期內血栓管理設備市場的成長。
此外,推動血栓管理設備需求的另一個主要因素是中風發生率的增加。 根據美國心臟協會(2023)提供的數據,2019年全球中風盛行率為1.015億人,其中缺血性中風7720萬人,腦出血2,070萬人,蜘蛛膜下腔出血840萬人。
此外,高血壓等與生活方式相關的疾病的增加也導致中風風險增加。 根據世界衛生組織關於高血壓的數據,截至2022年,全球近12.8億30歲至79歲的成年人患有高血壓。 據報導,高血壓不僅會損害心肌,還會導致出血性中風,例如短暫性腦缺血發作(TIA)。 高血壓被認為會導致大腦動脈狹窄,增加血栓形成的機會。 因此,高血壓族群的增加可能導致出血性中風的盛行率升高,而出血性中風通常會使用支架取栓器和抽吸血栓切除術來治療。 因此,由於上述因素,血栓管理設備市場預計將在預測期內顯著成長。
然而,與設備相關的併發症和頻繁的產品召回可能會抑制血栓管理設備市場的成長。
由於實施封鎖法規作為遏制 COVID-19 傳播的必要措施,血栓管理設備市場正在經歷暫時的挫折。 封鎖的主要影響之一是世界各地生產流程和供應鏈的中斷。 同時,優先考慮與 COVID-19 相關的患者負擔的醫療程序也顯著減少,這顯著減少了產品需求。 然而,隨著COVID-19疫苗在全球範圍內獲得批准和管理以及醫療服務等各個領域的活動開始,血塊管理設備市場正處於恢復階段,為血塊管理設備市場創造了有利的成長環境。 。
本報告研究和分析了全球血栓管理設備市場,提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。
Clot Management Devices Market By Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, And Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrieavble And Permanent], Compression Garments, And Others), And By End User (Hospitals, Ambulatory Surgical Centers, And Others), and by geography is estimated to register appreciable CAGR forecast till 2030 owing to increasing prevalence of strokes and embolsim due to rising geriatric population and lifestyle disorders such as hypertension
Global clot management devices market was valued at USD 1.76 billion in 2023, growing at a CAGR of 4.50% during the forecast period from 2024 to 2030 to reach USD 2.29 billion by 2030. The demand for clot management devices is primarily being boosted by increasing geriatric population who form a big part of at-risk population for developing thrombus, rising prevalence of lifestyle disorders such as hypertension and obesity which massively increase the chances of developing blood clots, and the innovation in product development leading to the development of second-generation thrombectomy devices ultimately contributing in the overall growth of the clot management devices market during the forecast period.
Clot Management Devices Market Dynamics:
The clot management devices market is experiencing increasing product demand owing to the variety of factors. One of the important factors is the increase in the elderly population. This is evident from the data provided by the World Health Organization in their Decade of Healthy Ageing (2020-2030) Report, the number of people aged 60 years and older will be 34% higher, increasing from one billion in 2019 to 1.4 billion in 2030. By 2050, the global population of older people will have more than doubled, to 2.1 billion. In addition to the above-mentioned stats, the factsheet on cardiovascular diseases published by the WHO further stated that more than four-fifths of deaths from cardiovascular diseases are primarily due to stroke and heart attack, and one-third of these deaths affect people under the age of 70. Old age or aging is considered as a major risk factor for numerous diseases as well as increasing the chances of developing thrombosis such as deep vein thrombosis (DVT). One of the major complications of DVT is pulmonary embolism, which can be fatal to the patient. Therefore, in order to avoid such serious consequences of thrombosis, a clot management device such as an inferior vena cava filter is used, among other interventions. Therefore, an increase in the elderly population, which may lead to an increase in the cases of DVT and further drive the demand for clot management devices, thereby contributing in the growth of the clot management devices market during the forecast period.
Moreover, another key factor responsible for driving the demand for clot management devices is the increasing incidence of brain strokes. As per the numbers provided by the American Heart Association (2023), the global prevalence of stroke in 2019 was 101.5 million people, whereas that of ischemic stroke was 77.2 million, that of intracerebral hemorrhage was 20.7 million, and that of subarachnoid hemorrhage was 8.4 million.
Furthermore, the rising prevalence of lifestyle disorders such as hypertension is also linked with increased risk of developing brain strokes. According to the data provided by the WHO on hypertension, as of 2022, near about 1.28 billion adults in the age group of 30-79 years across the globe have hypertension. High blood pressure has been reported to cause damage to the heart muscle as well as cause hemorrhagic strokes such as transient ischemic attack (TIA). Hypertension has been thought to cause the narrowing of arteries in the brain and increases the probability of blood clot formation. Therefore, this may indicate that the growing hypertensive population may result in the higher incidents of hemorrhagic strokes which are commonly treated with stent retrievers and aspiration thrombectomy. Therefore, the clot management devices market is slated to register remarkable growth during the forecast period owing to the factors mentioned above.
However, device-related complications and frequent product recalls may restrict the clot management devices market growth.
The clot management devices market has experienced a period of temporary recession as lockdown restrictions have been enforced as a necessary step to curb the spread of COVID-19 infections. One of the major impacts of lockdowns were observed in the disruption of production process and supply chains across the globe. Along with this, the significant decrease in the medical procedures due to prioritizing of COVID-19 infection-associated patient load, there was a striking decrease in the product demand because of that. However, the clot management devices market is in the recovery stage, with numerous COVID-19 vaccines being approved and administered worldwide, and activities have begun in various areas such as medical services thereby presenting a positive growth environment for the clot management devices market.
Clot Management Devices Market Segment Analysis:
Clot Management Devices Market by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena cava Filters [Retrievable and Permanent], Compression Garments, and Others), and by End User (Hospitals, Ambulatory Surgical Centers, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the clot management devices market, the stent retrievers' sub category in the thrombectomy devices category expected to amass a significant share in the market revenue during the forecast period. This can be ascribed to their advantages such as mechanical thrombectomy with stent retrievers is reported to produce superior clinical outcome in acute stroke patients compared to medical therapy alone. In addition to that, stent retrievers have a safety profile similar to that of systemic thrombolytic therapy.
Moreover, improvements in product design such as the incorporation of platinum for improved visibility (Trevo Provue and Solitaire Platinum) and longer lengths up to 40 mm have helped in improving the first-pass reperfusion outcomes. The entry of revoerable self-expanding thrombectomy devices further offer advantages such as he devices restore flow immediately and avoid the placement of a permanent stent, immediate restoration of blood and the eliminating the need for the placement of a permanent stent thereby reducing the chances of in-stent restenosis. Thus the factors mentioned above are expected to drive the demand for this product category, ultimately driving the clot management devices market forward.
North America is expected to dominate the overall Clot Management Devices Market:
Among all the regions, North America is estimated to account for the largest share in the clot management devices market. Owing to significance of key growth factors such as rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension and diabetes, the aging population, growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth. Furthermore, high disposable income, sophisticated healthcare infrastructure, new product approvals, and high awareness also helped the market growth in this region.
One of the key reasons positively influencing the growth of the United States clot management devices market is the rising prevalence of cancers in the US population. As per the latest data provided by American Cancer Society, around 1.9 million new cancer cases were diagnosed and 608,570 cancer deaths were reported in the United States in 2022. Cancer patients are thought to have specific abnormal coagulation factors which increase the chances of thrombus formation. Additionally, chemotherapy is also related with the increased risk of venous thrombosis resulting in deep vein thrombosis. Therefore, the rising prevalence of cancers in the country is expected to aid in the growing need for thrombus management devices thereby resulting in increase in product demand aiding in the growth of the United States clot management devices market.
Moreover, the rising prevalence of lifestyle disorders such as obesity is also considered as a key factor in the growing number of cases of clot formation in diseases such as DVT, brain strokes, and embolism. As per the data provided by the Canadian government (2023), in 2019, based on the body-mass index, approximately 56.5% of the Canadian population across all age groups was obese. Obesity is one of the most common factors that may result in embolism or DVT. Furthermore, obesity is also related with the inefficacy of anticoagulation therapeutics in obese patients. This further acts in the favor of thrombectomy and clot management devices. Therefore, the presence of large patient population suffering from obesity correlates to the presence of a high patient population suffering from as strokes, embolism, and DVT which would indicate the growing need for clot management equipment, thereby resulting in increase in product demand supporting the growth of the North America clot management devices market during the forecast period.
Clot Management Devices Market Key Players:
Some of the key market players operating in the clot management devices market includes Edward LifeSciences Corporation, Stryker, Johnson & Johnson, Medtronic, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd, Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook and others.
Recent Developmental Activities in Clot Management Devices Market:
In August 2022, Stryker Neurovascular received the regulatory approval from the US Food and Drug Administration (USFDA) for their Trevo NXT Pro Vue Retiever, a class II medical device classified as a neurovascular mechanical thrombectomy device for acute ischemic stroke.
In September 2022, Abbott announced the acquisition of Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots.
In February 2022, Inari Medical received the 510k approval for their Triever embelectomy catheters by the US FDA.
Key Takeaways from the Clot Management Devices Market Report Study
Market size analysis for clot management devices market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the clot management devices market.
Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
Key companies dominating the Global Clot Management Devices Market.
Various opportunities available for the other competitor in the Clot Management Devices Market space.
What are the top performing segments in 2023? How these segments will perform in 2030.
Which is the top-performing regions and countries in the current clot management devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for clot management devices market growth in the coming future?
Target Audience Who Can Be Benefited From This Clot Management Devices Market Report Study
Clot Management Devices products providers
Research organizations and consulting companies
Clot Management Devices-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in clot management devices
Various End-users who want to know more about the Clot Management Devices market and latest technological developments in the Clot Management Devices market.
Frequently Asked Questions for Clot Management Devices Market:
Clot management devices are medical devices that are employed in the removal blood clots from peripheral as well as neurovasculature.
Global clot management devices market was valued at USD 1.76 billion in 2023, growing at a CAGR of 4.50% during the forecast period from 2024 to 2030 to reach USD 2.29 billion by 2030.
The demand for clot management devices is primarily being boosted by increasing geriatric population who form a big part of at-risk population for developing thromboses, rising prevalence of lifestyle disorders such as hypertension and obesity which massively increase the chances of developing blood clots, and the innovation in product development leading to the development of second-generation thrombectomy devices ultimately contributing in the overall growth of the clot management devices market during the forecast period.
Some of the key market players operating in the clot management devices market includes Edward LifeSciences Corporation, Stryker, Johnson & Johnson, Medtronic, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd, Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook and others.
North America is expected to dominate the overall Clot Management Devices market during the forecast period. Owing to significance of key growth factors such as rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension and diabetes, the aging population, growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth. Furthermore, high disposable income, sophisticated healthcare infrastructure, new product approvals, and high awareness also helped the market growth in this region.